SU1720649A1 - Antiherpetic remedy "megosine" - Google Patents
Antiherpetic remedy "megosine" Download PDFInfo
- Publication number
- SU1720649A1 SU1720649A1 SU813332984A SU3332984A SU1720649A1 SU 1720649 A1 SU1720649 A1 SU 1720649A1 SU 813332984 A SU813332984 A SU 813332984A SU 3332984 A SU3332984 A SU 3332984A SU 1720649 A1 SU1720649 A1 SU 1720649A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- treatment
- antiherpetic
- patients
- dioxy
- oxo
- Prior art date
Links
- 230000003602 anti-herpes Effects 0.000 title claims description 3
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 3
- 206010020565 Hyperaemia Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000004317 sodium nitrate Substances 0.000 claims description 2
- 235000010344 sodium nitrate Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 239000002674 ointment Substances 0.000 abstract description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 abstract description 2
- 229940125721 immunosuppressive agent Drugs 0.000 abstract description 2
- 239000003018 immunosuppressive agent Substances 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052938 sodium sulfate Inorganic materials 0.000 abstract 1
- 235000011152 sodium sulphate Nutrition 0.000 abstract 1
- 230000003902 lesion Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- VYBIEVCNCDKLPV-MROCHPEUSA-L disodium;2-[[(z)-[7-[(8z)-1,6-dihydroxy-3-methyl-7-oxo-5-propan-2-yl-8-[(2-sulfonatoethylamino)methylidene]naphthalen-2-yl]-3,8-dihydroxy-6-methyl-2-oxo-4-propan-2-ylnaphthalen-1-ylidene]methyl]amino]ethanesulfonate Chemical compound [Na+].[Na+].CC(C)C1=C(O)C(=O)\C(=C/NCCS([O-])(=O)=O)C2=C(O)C(C=3C(O)=C4C(=C/NCCS([O-])(=O)=O)/C(=O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 VYBIEVCNCDKLPV-MROCHPEUSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Дл сокращени сроков лечени и удлинени сроков ремиссии примен ют у взрослых 3%-ную мазь 2,2-ди(1,6-диокси-5- изопропил-3-метил-7-оксо-8-метиаминоэт илсернокислый натрий)нафталина. У всех больных в течение 4-5 дней полностью исчезли признаки заболевани . Ранее данное соединение было известно как иммунодеп- рессивное средство.In order to shorten the treatment time and lengthen the remission period, adults use 3% ointment 2,2-di (1,6-dioxy-5-isopropyl-3-methyl-7-oxo-8-methiaminoethl sodium sulfate) naphthalene. In all patients within 4-5 days the signs of the disease completely disappeared. This compound has previously been known as an immunosuppressive agent.
Description
Изобретение относитс к медицине и может быть использовано дл лечени герпетических заболеваний.This invention relates to medicine and may be used to treat herpetic diseases.
Известно применение .противовирусного средства Амидаль дл лечени герпетических заболеваний.The use of the Amidal antiviral agent for the treatment of herpetic diseases is known.
Однако лечение носит длительный характер , причем заболевание проходит все стадии. Применение препарата Амидаль не ликвидирует заболевани полностью и не снижает числа рецидивов.However, the treatment is long, with the disease going through all stages. The use of the drug Amidal does not completely eliminate the disease and does not reduce the number of relapses.
Известно применение 2,2-ди(1,6-диок- си 5-изопропйл-3-метил-7-оксо-8-метиами- ноэтилсернокислый натрий) нафталина в качестве иммунодепрессивного средства.The use of 2,2-di (1,6-dioxy 5-isopropyl-3-methyl-7-oxo-8-methyamino-ethyl sulphate sodium) naphthalene as an immunosuppressive agent is known.
Цель изобретени - сокращение сроков лечени , удлинени сроков ремиссии.The purpose of the invention is to reduce the time of treatment, prolonging the periods of remission.
Цель достигаетс тем, что предложено примен ть у взрослых 2,2-ди(1,6-диокси-5- изопропил-3-метил-7-оксо-8-метиаминоэт- илсернокислый натрий) нафталин в качестве антигерпетического средства в виде 3%-ной мази, которую нанос т на пораженные участки кожи 2-3 раза в день, а в случае рецидивирующего течени заболевани - 5-6 раз.The goal is achieved by the fact that in adults it has been proposed to use 2,2-di (1,6-dioxy-5-isopropyl-3-methyl-7-oxo-8-methylaminoethyl sulfate sodium) naphthalene as an antiherpetic agent in the form of 3% ointment applied to the affected skin 2-3 times a day, and in the case of a relapsing course of the disease 5-6 times.
П р и м е р 1. Лечение мазью Мегосин провели на 22 больных С про вившимис PRI me R 1. Treatment with ointment Megosin conducted on 22 patients with advanced
впервые герпетическими высыпани ми. У всех пациентов отмечались зуд, чувство жжени , недомогание. Мазь наносилась тонким слоем на очаг поражени 2-3 раза в день, Ни у одного больного не было отмечено влений дерматита или каких-либо побочных влений. У 10 больных лечение было начато на 1-2-й день, у остальных - на 3-4-й день болезни. В случае начала лечени в ранние сроки заболевани при наличии отечности, гиперемии, единично развивающихс пузырьков уже после нескольких смазываний исчезали субъективные ощущени , приостанавливалось прегрессирование процесса и окончательный регресс наступал в течении 3-4 дней лечени . У всех больных в течение 4-5 дней наступали полное исчезновение признаков заболевани .for the first time herpetic rashes. All patients had itching, burning sensation, malaise. The ointment was applied in a thin layer to the lesion 2-3 times a day. No patient had any symptoms of dermatitis or any side effects. In 10 patients, treatment was started on the 1-2th day, in the rest - on the 3-4th day of illness. In the case of early treatment of the disease, in the presence of puffiness, hyperemia, and single-developing vesicles, subjective sensations disappeared after several lubrications, the process was regressed, and the final regression occurred within 3-4 days of treatment. In all patients, within 4-5 days, the complete disappearance of signs of the disease occurred.
П р и м е р 2. Лечение было проведено на 18 больных, страдавших частным рецидивами герпеса (до 3-4 раз в мес ц), мазь примен ли ежедневно 5-6 раз. Такое применение привело к прекращению по влени высыпаний и их развити у всех больных. При начале лечени в первые дни заболевани субъективные ощущени исчезают буквально в течение нескольких часов.EXAMPLE 2 The treatment was carried out on 18 patients who suffered from a recurrent herpes recurrence (up to 3-4 times per month), the ointment was applied daily 5-6 times. Such use has led to the cessation of the appearance of lesions and their development in all patients. At the beginning of treatment in the first days of the disease, the subjective sensations disappear literally within a few hours.
Процесс регрессируетс полностью в теме-ернокислый натрий) нафталина в качествеThe process regresses completely in the subject-sodium nitrate) naphthalene as
ние 2-3 дней лечени . Лечение, начатое вантмгерпетического средства у взрослых поразгаре процесса, также достаточно эффек-зволит снизить длительность лечени , уветивно ускор ет регресс высыпаний. У боль-личить сроки ремиссии при2-3 days of treatment. The treatment initiated by the adult means in adults after the process is also sufficiently effective to shorten the duration of the treatment and speeds up the regression of the lesions. The pain will have a remission time
ных рецидивирующим герпесом при5 рецидивирующих формах герпетических заприменении мази в первые часы рецидивовболеваний.recurrent herpes with 5 recurrent forms of herpetic application of ointment in the first hours of recurrence of diseases.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU813332984A SU1720649A1 (en) | 1981-08-06 | 1981-08-06 | Antiherpetic remedy "megosine" |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU813332984A SU1720649A1 (en) | 1981-08-06 | 1981-08-06 | Antiherpetic remedy "megosine" |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1720649A1 true SU1720649A1 (en) | 1992-03-23 |
Family
ID=20974974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU813332984A SU1720649A1 (en) | 1981-08-06 | 1981-08-06 | Antiherpetic remedy "megosine" |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1720649A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD995Z (en) * | 2015-01-27 | 2016-08-31 | Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова | Method for treating Herpes simplex virus type 1 and 2-induced infection |
-
1981
- 1981-08-06 SU SU813332984A patent/SU1720649A1/en active
Non-Patent Citations (1)
| Title |
|---|
| Авторское свидетельство СССР №545634, кл. С 07 С 7/28, 1977. . * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD995Z (en) * | 2015-01-27 | 2016-08-31 | Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова | Method for treating Herpes simplex virus type 1 and 2-induced infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sheskin | Thalidomide in the treatment of lepra reactions | |
| EDMUNDSON et al. | Treatment of psoriasis with folic acid antagonists | |
| West et al. | Effects of iproniazid in depressive syndromes | |
| Brodie et al. | Carbamazepine neurotoxicity precipitated by diltiazem | |
| US6034125A (en) | Method of treating depression using chromium | |
| Crane | Further studies on iproniazid phosphate: Isonicotinil-isopropylhydrazine phosphate Marsilid | |
| SU1720649A1 (en) | Antiherpetic remedy "megosine" | |
| Braun-Falco et al. | Erythemato-papulo-squamous diseases | |
| Siniscal | The sulfonamides and antibiotics in trachoma | |
| Forgays | Flotation REST as a smoking intervention | |
| INANAGA et al. | Effects of thyrotropin-releasing hormone in schizophrenia | |
| Black et al. | Streptomycin in tuberculous laryngitis | |
| US20070265238A1 (en) | Method for accelerating reentrainment of a circadian rhythm | |
| Maeda et al. | A trial of acupuncture for progressive systemic sclerosis | |
| RU2125457C1 (en) | Homeopathic drug "allergin-arn" for treatment of patients with allergosis | |
| RU2119350C1 (en) | Agent for treatment of patients with psoriasis | |
| Hackfield | STUDIES OF THE ETIOLOGICAL RELATIONSHIP BETWEEN THE SOMATIC AND PSYCHOTIC DISTURBANCES IN PENICIOUS ANEMIA: A Critical Review with Case Reports | |
| Doyle et al. | Use of milontin in the treatment of petit mal epilepsy (three per second spike and wave dysrhythmia) | |
| RU2004243C1 (en) | Method for treating psoriasis | |
| RU1801484C (en) | Method of keratic eczema treatment | |
| RU2111772C1 (en) | Method for treatment of psoriasis in its summer form | |
| Ed et al. | Effects of iproniazid in depressive syndromes. | |
| SU1734709A1 (en) | Method for treating the menopausal syndrome | |
| RU1821217C (en) | Method of treating psoriasis | |
| Houston | Tonics |